Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Hepatocellular 5Neoplasms 3Colorectal Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × brivanib × Clear all
NCT00798252 2015-07-07

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Bristol-Myers Squibb

Phase 1 Completed
111 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00207103 2008-11-04

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
68 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡